AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Fragile X Syndrome, Pipeline Review, H2 2019 - Healx Ltd, Novartis AG & Tetra Therapeutics - ResearchAndMarkets.com

January 9, 2020 GMT

DUBLIN--(BUSINESS WIRE)--Jan 9, 2020--

The “Fragile X Syndrome - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Report Highlights

The Publisher’s Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 5, 2 and 17 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

Reasons to buy

Key Topics Covered:

Introduction

Fragile X Syndrome - Overview

Fragile X Syndrome - Therapeutics Development

Fragile X Syndrome - Therapeutics Assessment

Fragile X Syndrome - Companies Involved in Therapeutics Development

Fragile X Syndrome - Drug Profiles

Fragile X Syndrome - Dormant Projects

Fragile X Syndrome - Discontinued Products

Fragile X Syndrome - Product Development Milestones

Appendix

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/p4q3xz

View source version on businesswire.com:https://www.businesswire.com/news/home/20200109005359/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: PROFESSIONAL SERVICES CONSULTING

SOURCE: Research and Markets

Copyright Business Wire 2020.

PUB: 01/09/2020 05:51 AM/DISC: 01/09/2020 05:51 AM

http://www.businesswire.com/news/home/20200109005359/en